Adaptimmune Therapeutics (ADAP) Stock Forecast, Price Target & Predictions
ADAP Stock Forecast
Adaptimmune Therapeutics stock forecast is as follows: an average price target of $2.83 (represents a 241.99% upside from ADAP’s last price of $0.83) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ADAP Price Target
ADAP Analyst Ratings
Adaptimmune Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 30, 2024 | Arthur He | H.C. Wainwright | $4.00 | $1.37 | 191.97% | 383.38% |
May 30, 2024 | George Farmer | Scotiabank | $3.15 | $1.01 | 211.88% | 280.66% |
May 17, 2024 | Graig Suvannavejh | Mizuho Securities | $3.00 | $1.20 | 150.00% | 262.54% |
May 16, 2024 | Peter Lawson | Barclays | $1.00 | $1.20 | -16.67% | 20.85% |
Nov 14, 2022 | - | Wells Fargo | $3.00 | $2.51 | 19.52% | 262.54% |
Adaptimmune Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $2.79 |
Last Closing Price | $0.83 | $0.83 | $0.83 |
Upside/Downside | -100.00% | -100.00% | 237.16% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 05, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
Aug 05, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
Jul 30, 2024 | H.C. Wainwright | - | Buy | Initialise |
May 31, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
May 30, 2024 | Scotiabank | - | Outperform | Initialise |
May 16, 2024 | Barclays | Underweight | Underweight | Hold |
Jan 03, 2023 | Guggenheim | - | Buy | Upgrade |
Nov 09, 2022 | Bank of America Securities | - | Buy | Upgrade |
Nov 09, 2022 | Mizuho Securities | - | Buy | Upgrade |
Adaptimmune Therapeutics Financial Forecast
Adaptimmune Therapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $231.00K | $7.32M | $5.13M | $47.60M | $11.03M | $7.01M | $5.54M | $3.58M | $1.42M | $1.20M | $3.10M | $434.00K | $1.50M | $1.19M | $502.00K | $761.00K | $728.00K | $237.00K |
Avg Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $18.57M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $3.50M | $4.50M | $1.53M | $1.40M | $1.83M | $1.80M | $1.02M | $7.94M | $23.29M | $1.30M | $1.48M |
High Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $22.90M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $3.50M | $4.50M | $1.53M | $1.40M | $1.83M | $1.80M | $1.02M | $7.94M | $23.29M | $1.30M | $1.48M |
Low Forecast | $629.08M | $536.64M | $457.79M | $390.52M | $11.33M | $9.23M | $7.63M | $6.23M | $11.08M | $14.23M | $40.47M | $9.88M | $25.96M | $7.97M | $6.13M | $5.15M | $3.83M | $6.93M | $6.57M | $3.50M | $4.50M | $1.53M | $1.40M | $1.83M | $1.80M | $1.02M | $7.94M | $23.29M | $1.30M | $1.48M |
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | 0.92% | 0.84% | 9.24% | 2.88% | 1.01% | 0.84% | 1.02% | 0.31% | 0.78% | 2.21% | 0.24% | 0.83% | 1.17% | 0.06% | 0.03% | 0.56% | 0.16% |
Adaptimmune Therapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-47.26M | $-46.29M | $-64.83M | $3.50M | $-27.24M | $-41.50M | $-42.20M | $-48.39M | $-36.41M | $-40.74M | $-37.55M | $-36.03M | $-34.84M | $-33.59M | $-27.70M | $-26.21M | $-27.18M | $-37.27M |
Avg Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-18.57M | $-40.47M | $-26.54M | $-25.96M | $-7.97M | $-6.13M | $-28.38M | $-31.16M | $-6.93M | $-6.57M | $-30.35M | $-4.50M | $-1.53M | $-1.40M | $-37.47M | $-1.80M | $-1.02M | $-7.94M | $-25.36M | $-1.30M | $-1.48M |
High Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-14.23M | $-40.47M | $-21.23M | $-25.96M | $-7.97M | $-6.13M | $-22.70M | $-24.92M | $-6.93M | $-6.57M | $-24.28M | $-4.50M | $-1.53M | $-1.40M | $-29.98M | $-1.80M | $-1.02M | $-7.94M | $-20.29M | $-1.30M | $-1.48M |
Low Forecast | $-629.08M | $-536.64M | $-457.79M | $-390.52M | $-11.33M | $-9.23M | $-7.63M | $-6.23M | $-11.08M | $-22.90M | $-40.47M | $-31.84M | $-25.96M | $-7.97M | $-6.13M | $-34.06M | $-37.39M | $-6.93M | $-6.57M | $-36.42M | $-4.50M | $-1.53M | $-1.40M | $-44.96M | $-1.80M | $-1.02M | $-7.94M | $-30.43M | $-1.30M | $-1.48M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.82% | 5.81% | 10.58% | -0.12% | 0.87% | 5.99% | 6.42% | 1.59% | 8.09% | 26.57% | 26.82% | 0.96% | 19.35% | 33.04% | 3.49% | 1.03% | 20.91% | 25.18% |
Adaptimmune Therapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-47.92M | $-45.60M | $-21.39M | $1.04M | $-29.25M | $-41.42M | $-44.52M | $-50.27M | $-38.86M | $-42.40M | $-39.07M | $-37.76M | $-36.61M | $-35.43M | $-29.88M | $-28.17M | $-29.36M | $-39.30M |
Avg Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.36M | $-3.04M | $-11.39M | $-27.96M | $-42.88M | $-50.41M | $-37.72M | $-29.91M | $-32.74M | $-64.97M | $-75.36M | $-31.99M | $31.70M | $-68.55M | $-9.74M | $-39.27M | $-60.63M | $-65.83M | $-61.50M | $-29.29M | $-88.35M | $-79.26M |
High Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.36M | $-1.79M | $-11.39M | $-22.37M | $-25.01M | $-50.41M | $-37.72M | $-23.93M | $-26.20M | $-64.97M | $-75.36M | $-25.59M | $31.70M | $-68.55M | $-9.74M | $-31.42M | $-60.63M | $-65.83M | $-61.50M | $-23.43M | $-88.35M | $-79.26M |
Low Forecast | $-42.77M | $-44.10M | $-47.63M | $-48.96M | $-31.96M | $-32.76M | $-32.42M | $-33.22M | $-7.36M | $-4.30M | $-11.39M | $-33.56M | $-57.17M | $-50.41M | $-37.72M | $-35.89M | $-39.29M | $-64.97M | $-75.36M | $-38.38M | $31.70M | $-68.55M | $-9.74M | $-47.13M | $-60.63M | $-65.83M | $-61.50M | $-35.15M | $-88.35M | $-79.26M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 0.90% | 0.57% | -0.03% | 0.89% | 0.64% | 0.59% | 1.57% | -1.23% | 0.62% | 4.01% | 0.96% | 0.60% | 0.54% | 0.49% | 0.96% | 0.33% | 0.50% |
Adaptimmune Therapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $16.88M | $16.16M | $20.07M | $20.40M | $15.22M | $16.82M | $16.89M | $16.80M | $15.48M | $15.17M | $14.99M | $13.82M | $13.24M | $13.00M | $10.29M | $9.26M | $10.73M | $10.74M |
Avg Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $232.67M | $507.13M | $9.35M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $43.86M | $56.39M | $19.21M | $17.54M | $22.97M | $22.56M | $12.74M | $99.53M | $9.63M | $16.29M | $18.55M |
High Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $287.01M | $507.13M | $11.22M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $43.86M | $56.39M | $19.21M | $17.54M | $22.97M | $22.56M | $12.74M | $99.53M | $11.56M | $16.29M | $18.55M |
Low Forecast | $7.88B | $6.72B | $5.74B | $4.89B | $142.02M | $115.70M | $95.65M | $78.11M | $138.84M | $178.33M | $507.13M | $7.48M | $325.30M | $99.89M | $76.80M | $64.53M | $48.04M | $86.82M | $82.35M | $43.86M | $56.39M | $19.21M | $17.54M | $22.97M | $22.56M | $12.74M | $99.53M | $7.71M | $16.29M | $18.55M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | 0.16% | 0.26% | 0.32% | 0.32% | 0.19% | 0.21% | 0.38% | 0.27% | 0.79% | 0.85% | 0.60% | 0.59% | 1.02% | 0.10% | 0.96% | 0.66% | 0.58% |
Adaptimmune Therapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.12 | $0.01 | $-0.18 | $-0.25 | $-0.28 | $-0.32 | $-0.25 | $-0.27 | $-0.25 | $-0.24 | $-0.24 | $-0.23 | $-0.22 | $-0.23 | $-0.28 | $-0.37 |
Avg Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.01 | $-0.04 | $-0.15 | $-0.17 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.25 | $0.12 | $-0.26 | $-0.04 | $-0.04 | $-0.23 | $-0.25 | $-0.24 | $-0.25 | $-0.34 | $-0.30 |
High Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.01 | $-0.04 | $-0.15 | $-0.10 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.25 | $0.12 | $-0.26 | $-0.04 | $-0.04 | $-0.23 | $-0.25 | $-0.24 | $-0.25 | $-0.34 | $-0.30 |
Low Forecast | $-0.16 | $-0.17 | $-0.18 | $-0.19 | $-0.12 | $-0.13 | $-0.12 | $-0.13 | $-0.03 | $-0.02 | $-0.04 | $-0.15 | $-0.22 | $-0.19 | $-0.15 | $-0.19 | $-0.24 | $-0.25 | $-0.29 | $-0.25 | $0.12 | $-0.26 | $-0.04 | $-0.04 | $-0.23 | $-0.25 | $-0.24 | $-0.25 | $-0.34 | $-0.30 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75% | 0.83% | -0.03% | 0.73% | 1.00% | 0.97% | 1.26% | -2.05% | 1.02% | 6.67% | 6.48% | 1.03% | 0.91% | 0.93% | 0.91% | 0.82% | 1.21% |
Adaptimmune Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ACET | Adicet Bio | $1.26 | $32.50 | 2479.37% | Buy |
SGMO | Sangamo Therapeutics | $1.74 | $12.00 | 589.66% | Buy |
NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
AGIO | Agios Pharmaceuticals | $44.83 | $48.71 | 8.65% | Buy |
CRVS | Corvus Pharmaceuticals | $9.02 | $9.50 | 5.32% | Buy |
ADAP Forecast FAQ
Is Adaptimmune Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Adaptimmune Therapeutics (ADAP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ADAP's total ratings.
What is ADAP's price target?
Adaptimmune Therapeutics (ADAP) average price target is $2.83 with a range of $1 to $4, implying a 241.99% from its last price of $0.828. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adaptimmune Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ADAP stock, the company can go up by 241.99% (from the last price of $0.828 to the average price target of $2.83), up by 383.38% based on the highest stock price target, and up by 20.85% based on the lowest stock price target.
Can Adaptimmune Therapeutics stock reach $1?
ADAP's average twelve months analyst stock price target of $2.83 supports the claim that Adaptimmune Therapeutics can reach $1 in the near future.
What are Adaptimmune Therapeutics's analysts' financial forecasts?
Adaptimmune Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.43M (high $34.43M, low $34.43M), average EBITDA is $-34.433M (high $-34.433M, low $-34.433M), average net income is $-130M (high $-130M, low $-130M), average SG&A $431.48M (high $431.48M, low $431.48M), and average EPS is $-0.502 (high $-0.502, low $-0.502). ADAP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.01B (high $2.01B, low $2.01B), average EBITDA is $-2.014B (high $-2.014B, low $-2.014B), average net income is $-183M (high $-183M, low $-183M), average SG&A $25.24B (high $25.24B, low $25.24B), and average EPS is $-0.706 (high $-0.706, low $-0.706).
Did the ADAP's actual financial results beat the analysts' financial forecasts?
Based on Adaptimmune Therapeutics's last annual report (Dec 2023), the company's revenue was $60.28M, beating the average analysts forecast of $45.21M by 33.34%. Apple's EBITDA was $-115M, beating the average prediction of $-68.44M by 68.33%. The company's net income was $-114M, missing the average estimation of $-161M by -29.24%. Apple's SG&A was $73.51M, missing the average forecast of $566.52M by -87.02%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.69 by -99.99%. In terms of the last quarterly report (Dec 2023), Adaptimmune Therapeutics's revenue was $231K, missing the average analysts' forecast of $25.96M by -99.11%. The company's EBITDA was $-47.261M, beating the average prediction of $-25.96M by 82.05%. Adaptimmune Therapeutics's net income was $-47.917M, beating the average estimation of $-42.878M by 11.75%. The company's SG&A was $16.88M, missing the average forecast of $325.3M by -94.81%. Lastly, the company's EPS was $0, missing the average prediction of $-0.165 by -100.00%